Written by specialists in the different fields, this book presents new perspectives and insights into strategies and weapons to fight microbial infections. It also reviews the "state of the art" of alternative treatment approaches and new therapeutic agents to deal with infections caused by multidrug-resistant microorganisms. In an era of accumulated resistance to current antibiotics, it is vital that this is undertaken without further delay. Aspects discussed include the control of RNA synthesis, the use of bacteriocins or enzybiotics (bacteriophages or purified lysins), the specific control of pathogenic clostridia, the design of new drugs affecting DNA synthesis in bacteria, the use of fecal-matter transplant strategies, the specific control of quorum sensing responses in bacteria, the use of new peptides as antibiotics and new ways to control bacteria that cause cancer, such as Helicobacter pylori cancers.

Since penicillin and salvarsan were discovered, a number of new drugs to combat infectious diseases have been developed, but at the same time, the number of multi-resistant microorganism strains is increasing. Thus, the design of new and effective antibacterial, antiviral and antifungal agents will be a major challenge in the next years. This book reviews the current state-of-the-art in antimicrobial research and discusses new strategies for the design and discovery of novel therapies. Topics covered include the use of genetic engineering, genome mining, manipulation of gene clusters, X-ray and neutron scattering as well as the antimicrobial effects of essential oils, antimicrobial agents of plant origin, beta-lactam antibiotics, antimicrobial peptides, and cell-wall-affecting antifungal antibiotics.

The book focuses on the evolutionary impact of horizontal gene transfer processes on pathogenicity, environmental adaptation and biological speciation. Newly acquired genetic material has been considered as a driving force in evolution for prokaryotic genomes for many years, with recent technical developments advancing this field further. However, the extent and implications of gene transfer between prokaryotes and eukaryotes still raise controversies. This multi-authored volume introduces various means by which DNA can be exchanged, covers gene transfer between prokaryotes and their viruses as well as between bacteria and eukaryotes, such as fungi, plants and animals, and addresses the role of horizontal gene transfer in human diseases. Aspects discussed also include the relevance for virulence and drug resistance development on one hand, and for the occurrence of naturally derived antibiotics and other secondary metabolites on the other hand. This book offers new insights to anyone interested in genome evolution and the exchange of DNA between the different domains of life, the genetic toolkit for adaptation and the emergence of multidrug resistant bacteria.

The book focuses on the evolutionary impact of horizontal gene transfer processes on pathogenicity, environmental adaptation and biological speciation. Newly acquired genetic material has been considered as a driving force in evolution for prokaryotic genomes for many years, with recent technical developments advancing this field further. However, the extent and implications of gene transfer between prokaryotes and eukaryotes still raise controversies. This multi-authored volume introduces various means by which DNA can be exchanged, covers gene transfer between prokaryotes and their viruses as well as between bacteria and eukaryotes, such as fungi, plants and animals, and addresses the role of horizontal gene transfer in human diseases. Aspects discussed also include the relevance for virulence and drug resistance development on one hand, and for the occurrence of naturally derived antibiotics and other secondary metabolites on the other hand. This book offers new insights to anyone interested in genome evolution and the exchange of DNA between the different domains of life, the genetic toolkit for adaptation and the emergence of multidrug resistant bacteria.

Written by specialists in the different fields, this book presents new perspectives and insights into strategies and weapons to fight microbial infections. It also reviews the "state of the art" of alternative treatment approaches and new therapeutic agents to deal with infections caused by multidrug-resistant microorganisms. In an era of accumulated resistance to current antibiotics, it is vital that this is undertaken without further delay. Aspects discussed include the control of RNA synthesis, the use of bacteriocins or enzybiotics (bacteriophages or purified lysins), the specific control of pathogenic clostridia, the design of new drugs affecting DNA synthesis in bacteria, the use of fecal-matter transplant strategies, the specific control of quorum sensing responses in bacteria, the use of new peptides as antibiotics and new ways to control bacteria that cause cancer, such as Helicobacter pylori cancers.